Hormonal
SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) significantly reduce the risk of hospitalization for heart failure in patients with type 2 diabetes, independent of glycemic control.
If you have Type 2 Diabetes and are at risk for heart failure, ask your doctor about SGLT2 inhibitors (like empagliflozin or dapagliflozin). These drugs have been proven in large studies to significantly lower the risk of hospitalization for heart failure, even independent of their blood sugar-lowering effects. This is a key preventive strategy for heart health in diabetes.
recently, a large body of basic and clinical research has elucidated that the cardioprotective effects of SGLT2 inhibitors in patients with T2DM and non-diabetic patients are independent of their antihyperglycemic effects... empagliflozin was superior to placebo in reducing the risk of MACE, as well as decreasing the relative risk of hospitalization for HF by 35%... dapagliflozin... was associated with a significant 17% reduction in the composite endpoint of cardiovascular death or first hospitalization for HF, primarily driven by a 27% reduction in first hospitalization for HF... canagliflozin reduced the relative risk of... hospitalization for HF by 39%.
Why this rating
Based on multiple large-scale randomized controlled trials (EMPA-REG, DECLARE-TIMI 58, CANVAS, VERTIS CV, DAPA-CKD) cited in the review.
Source
Type 2 diabetes mediated heart failure: focus on early recognition and clinical strategies
Xi Chen et al. · Frontiers in Endocrinology · 2025
DOI 10.3389/fendo.2025.1630686
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →